Industry News
Biotechnology Industry News

Protagonist posts phase 2 hormone replacement data, pitching for lead role in genetic iron overload disease
Protagonist posts phase 2 hormone replacement data, pitching for lead role in genetic iron overload disease ntaylor Mon, 11/15/2021 - 09:02
AHA: AstraZeneca, Moderna shine early light on mRNA potential in heart failure
AHA: AstraZeneca, Moderna shine early light on mRNA potential in heart failure badams Mon, 11/15/2021 - 09:01
Twist spins out COVID-19 antibody program, forming startup to advance variant-busting candidate
Twist spins out COVID-19 antibody program, forming startup to advance variant-busting candidate ntaylor Mon, 11/15/2021 - 08:06
SITC: Cellectis’ off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice
SITC: Cellectis' off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice arlene.weintraub Fri, 11/12/2021 - 10:34
UPDATED: At the eleventh hour, Woodcock shunned by Biden as Califf becomes FDA commish nominee
UPDATED: At the eleventh hour, Woodcock shunned by Biden as Califf becomes FDA commish nominee badams Fri, 11/12/2021 - 10:34
Gerngross biotech Ankyra Therapeutics nabs $45M series B to jump into the clinic, hires new CMO
Gerngross biotech Ankyra Therapeutics nabs $45M series B to jump into the clinic, hires new CMO badams Fri, 11/12/2021 - 08:28
AstraZeneca wields ax, scrapping midphase programs from $1B takeover, Heptares pact in latest quarterly cull
AstraZeneca wields ax, scrapping midphase programs from $1B takeover, Heptares pact in latest quarterly cull ntaylor Fri, 11/12/2021 - 06:05
Adaptimmune’s TCR T-cell therapy clears efficacy bar in rare cancers, teeing up landmark solid tumor filing
Adaptimmune's TCR T-cell therapy clears efficacy bar in rare cancers, teeing up landmark solid tumor filing ntaylor Fri, 11/12/2021 - 04:48
Using CRISPR to find a new drug target for multiple sclerosis, inflammatory bowel disease
Using CRISPR to find a new drug target for multiple sclerosis, inflammatory bowel disease klahucik Thu, 11/11/2021 - 16:53
Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut
Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut badams Thu, 11/11/2021 - 08:50
Organon keeps pedal to the metal, buying up Forendo in 3rd deal since spinning out of Merck
Organon keeps pedal to the metal, buying up Forendo in 3rd deal since spinning out of Merck ntaylor Thu, 11/11/2021 - 08:28
Genentech, Novome team up to study seaweed-controlled oral cell therapies in IBD
Genentech, Novome team up to study seaweed-controlled oral cell therapies in IBD ntaylor Thu, 11/11/2021 - 07:51
After snapping up Parexel with Goldman Sachs, EQT doubles down on healthcare with Life Sciences Partners buyout
After snapping up Parexel with Goldman Sachs, EQT doubles down on healthcare with Life Sciences Partners buyout badams Wed, 11/10/2021 - 08:20
Immatics’ cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help?
Immatics' cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help? ntaylor Wed, 11/10/2021 - 08:06
Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel
Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel aliu Wed, 11/10/2021 - 07:41
Psilocybin clears biggest depression test yet, but Compass stock falls amid chatter about adverse events, durability
Psilocybin clears biggest depression test yet, but Compass stock falls amid chatter about adverse events, durability ntaylor Wed, 11/10/2021 - 05:30
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf badams Wed, 11/10/2021 - 04:37
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target ntaylor Tue, 11/09/2021 - 08:08
Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability
Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability ntaylor Tue, 11/09/2021 - 06:54
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer arlene.weintraub Mon, 11/08/2021 - 09:33

